Therapeutic Area | MeSH |
---|---|
ocular physiological phenomena | D009799 |
Brand Name | Status | Last Update |
---|---|---|
omlonti | New Drug Application | 2023-10-09 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
intraocular pressure | — | D007429 | — |
Expiration | Code | ||
---|---|---|---|
OMIDENEPAG ISOPROPYL, OMLONTI, SANTEN | |||
2027-09-22 | NCE |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Omidenepag Isopropyl, Omlonti, Santen | |||
11666563 | 2039-07-16 | U-3454 | |
10774072 | 2035-06-10 | DP | |
RE48183 | 2035-01-08 | DP | U-3454 |
9415038 | 2035-01-08 | DP | U-3454 |
10179127 | 2035-01-08 | DP | U-3454 |
10702511 | 2035-01-08 | DP | U-3454 |
10765750 | 2035-01-08 | DP | |
11197849 | 2035-01-08 | DP | U-3454 |
8648097 | 2029-10-13 | DS, DP | |
8685986 | 2029-10-13 | DP |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hypertension | D006973 | EFO_0000537 | I10 | 1 | 5 | 7 | 1 | — | 12 |
Ocular hypertension | D009798 | EFO_1001069 | H40.0 | 1 | 5 | 7 | 1 | — | 12 |
Glaucoma | D005901 | EFO_0000516 | H40 | 1 | 5 | 7 | 1 | — | 12 |
Open-angle glaucoma | D005902 | EFO_0004190 | H40.1 | — | 4 | 5 | 1 | — | 9 |
Low tension glaucoma | D057066 | EFO_1001022 | H40.12 | — | — | — | 1 | — | 1 |
Drug common name | Omidenepag isopropyl |
INN | — |
Description | Omidenepag, sold under the brand name Eybelis among others, is a medication used for the treatment of glaucoma and ocular hypertension.
|
Classification | Small molecule |
Drug class | non-prostanoid prostaglandin receptor agonists |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CC(C)OC(=O)CNc1cccc(CN(Cc2ccc(-n3cccn3)cc2)S(=O)(=O)c2cccnc2)n1 |
PDB | — |
CAS-ID | 1187451-19-9 |
RxCUI | — |
ChEMBL ID | CHEMBL4297666 |
ChEBI ID | — |
PubChem CID | 44230999 |
DrugBank | DB15071 |
UNII ID | — |